Noom, a digital healthcare company, is revolutionizing the weight loss industry with its new program, Noom GLP-1Rx. This innovative offering combines affordable, compounded GLP-1 injections with Noom’s established behavioral change program to provide a comprehensive weight loss solution. The program includes medications delivered directly to the patient’s door within seven days, starting at $149, and is paired with the Noom GLP-1 Companion with Muscle Defense.
The program addresses significant challenges related to obesity and GLP-1 medications, including high costs and limited availability. Brand-name GLP-1 medications are often prohibitively expensive in the U.S., with prices around $1,349 per month, compared to much lower costs abroad. Additionally, drug shortages frequently hinder access. Noom GLP-1Rx mitigates these issues by offering compounded semaglutide at a reduced price and ensuring convenience through direct delivery and thorough evaluations by board-certified obesity experts.
To support long-term weight management, Noom includes a Taper-Off Guarantee, which provides continued support and discounted future medication for participants who regain weight after completing the 12-month program. The approach combines medication with behavioral coaching to enhance sustainable weight loss.
Noom’s CEO, Geoff Cook, highlighted the need for regulatory changes to address the high cost of brand-name medications in the U.S., advocating for lower prices or continued compounding exemptions to meet the substantial demand.
Click here to read the original news story.